Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)

BACKGROUND: Carfilzomib and other proteasome inhibitors (PIs) have revolutionized treatment of multiple myeloma (MM). PIs have proven to be highly effective, but are associated with significant cardiovascular adverse events (AEs). No prior study has compared the cardiotoxicity of carfilzomib against...

Descripción completa

Detalles Bibliográficos
Autores principales: Buck, Benjamin, Kellett, Eric, Addison, Daniel, Vallakati, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Heart Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458320/
https://www.ncbi.nlm.nih.gov/pubmed/36127934
http://dx.doi.org/10.37616/2212-5043.1311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458320/
https://www.ncbi.nlm.nih.gov/pubmed/36127934
http://dx.doi.org/10.37616/2212-5043.1311

Ejemplares similares